22252-07-9
Chemical Structure
Lysophosphatidylcholine 18:2
Synonym(s): 1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC(18:2/0:0); LysoPC(18:2)
- CAS No.: 22252-07-9
- Formula:C26H50NO7P
- Molecular Weight:519.65
IUPAC Name: (R)-2-hydroxy-3-(((9Z,12Z)-octadeca-9,12-dienoyl)oxy)propyl (2-(trimethylammonio)ethyl) phosphate
InChIKey: SPJFYYJXNPEZDW-FTJOPAKQSA-N
SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O)=O
Biological Activity: Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lysophosphatidylcholine 18:2 | 99.12% | Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lysophosphatidylcholine 18:2-d9 | 98.0% | Lysophosphatidylcholine 18:2-d9 is deuterium labeled Lysophosphatidylcholine 18:2. Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gonzalez-Freire M, et al. Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2019;74(1):62-67. [Content Brief]
- [2]. Chen YX, et al. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal. 2016;121:141-150. [Content Brief]
